Medscape Conference Coverage, based on selected sessions at the:
29th Annual San Antonio Breast Cancer Symposium
December 14 - 17, 2006, San Antonio, Texas

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium.


Also On This Page:Expert InterviewConference News
Topic Overviews
CME Evolving Therapeutic Options for Patients With Early Breast Cancer
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
•Update on Adjuvant Chemotherapy in Breast Cancer
Heather L. McArthur, MD
Clifford A. Hudis, MD
•Management of HER-2-Overexpressing Early Breast Cancer
Harold J. Burstein, MD, PhD
•Refining and Improving Endocrine Therapies in the Adjuvant Breast Cancer Setting
Harold J. Burstein, MD, PhD

CME New Directions for Patients With Advanced Breast Cancer
Physicians - maximum of 0.5 AMA PRA Category 1 credit(s)™
•Novel Therapeutic Directions for Patients With Advanced Breast Cancer
Mohammad Jahanzeb, MD, FACP
Jasgit C. Sachdev, MD
•Targeting HER2/Neu: A Continually Evolving Strategy in Advanced Breast Cancer
Harold J. Burstein, MD, PhD

CME Customizing Breast Cancer Treatment
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
•Identifying Predictive Factors in the Treatment of Breast Cancer
Kathleen I. Pritchard, MD, FRCPC
•Basic Science Advances in the Understanding of Breast Cancer
Kathleen I. Pritchard, MD, FRCPC

Expert Interview
Gene-Expression Signatures -- Clinical Implications for Breast Cancer Therapy: An Expert Interview With Dr. Joseph Sparano
Dr. Joseph Sparano discusses use of molecular diagnostic tests based on gene-expression profiles to guide treatment decisions for patients with early breast cancer.


Conference News
Hurdles Remain in Bringing Antiangiogenics to Clinical Practice 1/8/07
[Medscape Medical News]
Agents targeting vascular endothelial growth factor are showing great promise, and some say they could become the standard of care in the frontline treatment of metastatic breast cancer, but many questions have yet to be answered as researchers investigate.
Joint Symptoms and Other Side Effects of Aromatase Inhibitors 12/22/06
[Medscape Medical News]
New reports on side effects with aromatase inhibitors suggest that joint symptoms are more prevalent and more severe than have previously been described in clinical trials.
Grid Helps Physicians Decide Who Should Take Tamoxifen 12/21/06
[Medscape Medical News]
A simple grid is available to help physicians decide whether a patient is suitable for tamoxifen for breast cancer prevention.
Anthracyclines May Not Be Necessary in Adjuvant Therapy of Breast Cancer 12/18/06
[Medscape Medical News]
Updated study results showing that a regimen of taxane and trastuzumab has similar survival rates but less toxicity than a regimen containing doxorubicin have raised questions over the role of anthracyclines in adjuvant therapy.
Breast Cancer Vaccine May Prevent Recurrence 12/18/06
[Medscape Medical News]
Rather than treat metastatic disease, the HER2/neu vaccine, dubbed E75 after its immunogenic peptide, is designed to reduce recurrence in high-risk patients.
Oncologists Should Work Like Cardiologists, Researchers Say 12/18/06
[Medscape Medical News]
Cancer doctors are too focused on treatment and don't spend enough time on prevention, says a researcher from the National Cancer Institute.
Breast Density Not Predictive for Invasive Cancer in DCIS 12/18/06
[Medscape Medical News]
High breast density does not predict which women with ductal carcinoma in situ will go on to develop invasive breast cancer.
Tamoxifen Continues to Prevent Breast Cancer for Years After Therapy Is Stopped 12/18/06
[Medscape Medical News]
Tamoxifen continues to exert protective effects against breast cancer for years after therapy is stopped, whereas the side effects disappear as soon as the drug is no longer taken, which substantially improves the risk/benefit ratio.
Fulvestrant New Option for Breast Cancer Patients Who Have Failed Aromatase Therapy 12/15/06
[Medscape Medical News]
Results of a randomized phase 3 trial show that the estrogen receptor downregulator is a safe and effective alternative for postmenopausal women with advanced breast cancer.
Lapatinib Alone Effective in Inflammatory Breast Cancer 12/14/06
[Medscape Medical News]
Tested for the first time in patients with newly diagnosed inflammatory breast cancer, the investigational drug showed activity alone and in combination with paclitaxel.
Sudden Decline in Breast Cancer Could Be Linked to HRT 12/14/06
[Medscape Medical News]
A surprising 7% decrease in breast cancer incidence was observed in 2003 - a dramatic fall that never before has been observed in a single year. Researchers are attributing the promising decline, which was most noticeable in patients older than 50 years, to changes in hormone therapy use.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2007 Medscape.

 
Genomic Health
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.